September 2nd 2020EP. 1: Patient Journey and Development of Metastatic Breast Cancer
September 2nd 2020EP. 2: Patient, Advocate, and Payer on Value-Based Care for mBC
September 2nd 2020EP. 3: Provider Perspective on Value-Based Care for mBC
September 2nd 2020EP. 4: Patient Cost Burden for Metastatic Breast Cancer Therapy
September 2nd 2020EP. 5: Provider Responsibility to Cost Burden for mBC Therapy
September 2nd 2020EP. 6: Value-Based Care vs Cost of Treatment for mBC
September 2nd 2020EP. 7: First-line Therapy for HR-Positive, HER2-Negative mBC
September 2nd 2020EP. 8: Pivotal Studies for CDK4/6 Inhibitors
September 2nd 2020EP. 9: Role of CDK4/6 Inhibitors and Patient Selection
September 2nd 2020EP. 10: Distinguishing Among the Available CDK4/6 Inhibitors
September 2nd 2020EP. 11: Formulary Consideration and Clinical Impact of Cost
September 2nd 2020EP. 12: Breast Cancer Management: Global Cost of Care
September 2nd 2020EP. 13: Defining Episode of Care in Metastatic Disease
September 2nd 2020EP. 14: Breast Cancer Pathway Guidelines for Practitioners
September 2nd 2020EP. 15: Payer Approval for Frontline Options: Restrictive or Broad?
September 2nd 2020EP. 16: The Impact of Patient Preference on Payer Compliance
September 2nd 2020EP. 17: Breast Cancer Treatment: How COVID-19 Has Altered Care
September 2nd 2020EP. 18: Adjuvant CDK4/6 Inhibition: When it Will Become Routine
September 2nd 2020EP. 19: Development of Clinical Pathways and Patient Characteristics
September 2nd 2020EP. 20: Adding Multiple in a Class and Measuring Success of Pathways
September 2nd 2020EP. 21: Outcomes and Future of Clinical Pathways
